Biotechnology for Healthy Ageing
eu HORIZON-EIC-PATHFINDERCHALLENGES-01-02 · Horizon Europe (HORIZON)
| Status | forthcoming |
|---|---|
| Opens | 22 Jul 2026 |
| Deadline | 28 Oct 2026 — 45 days |
| Action | HORIZON EIC Grants |
| Official page | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunit… |
| Fetched | 2026-09-13 04:00:37+00:00 |
You are reading one call. 1,385 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
Free · no account · nothing stored that identifies youScope
Expected Impact: This Challenge looks to accelerate the development and uptake of clinically validated interventions that target the root cause of multiple age-related morbidities. It will: Deliver biotechnology-based interventions for healthy ageing Accelerate the implementation of personalised care in ageing based on molecular phenotyping Provide recommendations for regulatory pathways addressing ageing as a target to inform developers, regulators, and other decision makers, and Improve citizen literacy on longevity. Expected Outcome: Ambitious proposals put forward under this call will deliver: Proof-of-concepts (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an intervention Tools to facilitate development or adoption of the interventions above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models, and Approaches to address the shared regulatory hurdles and societal challenges linked to ageing-related interventions, thereby facilitating their adoption. Portfolio approach The portfolio of projects selected under this Challenge will ensure a coverage of projects developing interventions, biomarkers and NAMs, considering the following guidelines for portfolio composition: Interventions: no more than 5 projects. The portfolio of selected projects should collectively address a variety molecular and cellular processes related to ageing, and a variety of different age-related diseases. Biomarkers: no more than 3 projects. Projects will be selected to capture different application areas (diagnostic, predictive, prognostic biomarker), with preference to the inclusion of at least one diagnostic biomarker). NAMs: No more than 2 projects. Projects will be selected to capture a diversity of approaches to assess aged status in NAMs, different tissues or cell types and different use cases. The selected consortia will benefit from mutual learning, and the exchange of expertise. Consortia will be encouraged to collaborate to address the following shared challenges faced by all ageing interventions: Scientific: preclinical models; Biomarkers of healthy/unhealthy ageing Path to Market: Defining suitable regulatory pathways, and Societal: Acceptance and role of preventative / therapeutic interventions, Need for improved longevity literacy. Objective: Applicants to this Challenge will be expected to de…
What consortia for this call have looked like
40 projects
have been funded under this line
(HORIZON-EIC-PATHFINDERCHALLENGES-01-02) in Horizon Europe and H2020. This is what they
were made of — not a recommendation, just what the Commission signed.
range 2–13
33 seen across all of them
across those projects
The mix of organisations
Who coordinated them
Coordinating an EU project is a demanding, specific job. These organisations have done it on this topic line before.
This is the shape, not the consortium. It says how many partners these projects had and what kinds of organisation were in them. It does not know whether your idea needs the same mix, who is available, who is already committed elsewhere, or how the work and the budget should be divided. Those are judgement calls on a specific proposal, and no amount of public data answers them.
Building the actual consortium — finding the partners, agreeing the roles, and writing it so it survives an evaluation — is what Scientific Network Management does. Free either way; the radar does not change if you never ask.
Finding the call is the easy half. Scientific Network Management is the grant-writing practice behind this radar — 13 years of writing and managing EU-funded research projects, including two EuropeAid technical assistance contracts building biotechnology centres in Türkiye as Team Leader.
Talk to us What SNM does No obligation, and nothing here is conditional on using us — the radar stays free and complete either way.